Active Filter(s):
Details:
The merger creates a growing commercial pharmaceutical company with neurology, inflammation and pain products.
Lead Product(s): Diclofenac Potassium
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Assertio Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 20, 2020